FUJIFILM DIOSYNTH BIOTECHNOLOGIES EXPANDS ITS PROCESS CHARACTERIZATION OFFERING
2020-12-16
Billingham, United Kingdom, December 16, 2020 – FUJIFILM Diosynth Biotechnologies, a world leading Contract Development and Manufacturing Organization (CDMO) providing end-to-end services for the development and manufacture of biologics, viral vaccines and viral vectors, is doubling its existing process characterization capacity. FUJIFILM Diosynth Biotechnologies will expand its global process characterization offering with the addition of dedicated laboratories in the North East of the United Kingdom (U.K.) by late fall 2021.
As a critical step in the full lifecycle of biopharmaceutical drug development, process characterization enables consistent product quality via effective process control strategies to ensure successful process validation and commercial manufacture.
“We have unrivaled experience in the validation of drug manufacturing processes, having completed over 70 process characterization programs across a wide range of molecules and manufacturing modalities,” said Andy Fenny, Chief Business Officer, FUJIFILM Diosynth Biotechnologies. “We are delighted to expand our process characterization footprint in the U.K. to provide industry leading services to support our growing number of late-phase programs and stand-alone projects.”
The additional laboratories will provide state-of-the-art process and analytical equipment to fulfill the stringent quality standards required by process characterization studies.
“This expansion exemplifies our core purpose to developing long-term relationships with our customers to support all stages of their product’s clinical, and eventually, commercial trajectory,” added Andy.
About FUJIFILM
FUJIFILM Diosynth Biotechnologies is an industry-leading Biologics Contract Development and Manufacturing Organization (CDMO) with locations in Teesside, UK, RTP, North Carolina, College Station, Texas and Hillerød, Denmark. FUJIFILM Diosynth Biotechnologies has over thirty years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway™ microbial and Apollo™X cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. FUJIFILM Diosynth Biotechnologies is a partnership between FUJIFILM Corporation and Mitsubishi Corporation. For more information, go to: www.fujifilmdiosynth.com
FUJIFILM Corporation is an operating company of FUJIFILM Holdings Corporation. FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2020, the company had global revenues of $21 billion, at an exchange rate of 109 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com
Media Contact:
Christine Jackman
Fujifilm
(914) 261-4959
christine.jackman@fujifilm.com
[1] Good Manufacturing Practice